| Azacitidine for anemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Benserazide Only Product for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Benserazide Only Product for beta-thalassemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BMS-986470 for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BMS-986470 + Famotidine + PANTOPRAZOLE for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BMS-986470 + Placebo for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) for anemia, sickle cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Crizanlizumab for anemia, sickle cell | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cyclophosphamide for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Danicopan for hemoglobinuria, paroxysmal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for anemia, sickle cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| EDIT-301 for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elritercept for anemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Exagamglogene autotemcel for anemia, sickle cell | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
|---|
| Exagamglogene autotemcel for beta-thalassemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Exerenibart for beta-thalassemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Busulfan + FLUDARABINE + Melphalan + Mycophenolate Mofetil Hydrochloride for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Total Body Irradiation (TBI) + Cyclophosphamide + FLUDARABINE + Mycophenolate Mofetil Hydrochloride + Tacrolimus for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GVHD prophylaxis regimen + RIC regimen for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hydroxycarbamide for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Iloprost for vaso-occlusive crises | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Iron sucrose for anemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Isatuximab for anemia, aplastic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Luspatercept for anemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
|---|
| Mitapivat for anemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mobilized CD34-selected Peripheral Blood Stem Cell graft for anemia, refractory, with excess of blasts | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Established Dose from prior study, NCT03810196 for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Placebo for Oral Azacitidine for anemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pozelimab + cemdisiran for hemoglobinuria, paroxysmal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton Total Marrow Irradiation for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia for anemia, aplastic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rivogenlecleucel + rimiducid for anemia, aplastic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Romiplostim for anemia, aplastic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Romiplostim for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ruxoprubart for hemoglobinuria, paroxysmal | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation for anemia, sickle cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| thrombopoietin receptor agonist (TPO-RA) + Cyclosporine + ROMIPLOSTIM for anemia, aplastic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blasts | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + THIOTEPA + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blasts | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tranexamic acid for anemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Unmanipulated Bone Marrow Graft with Cyclophosphamide + Cyclophosphamide for anemia, refractory, with excess of blasts | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|